SCHEMBL3473947

SCHEMBL3473947

CC(C)c1nc2c(=O)n(C)c(=O)nc-2n(C)n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP2 O95551 15/20 0.65
KDM4C Q9H3R0 7/20 0.65
NPC1 O15118 4/20 0.65
POLB P06746 4/20 0.65
MAPT P10636 4/20 0.65
RAB9A P51151 4/20 0.65
GALK1 P51570 4/20 0.65
BLM P54132 4/20 0.65
NPSR1 Q6W5P4 4/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
L3MBTL1 Q9Y468 3/20 0.65
ABL1 P00519 3/20 0.65
RIN1 Q13671 3/20 0.65
RAF1 P04049 3/20 0.65
MAP2K1 Q02750 3/20 0.65
LMNA P02545 3/20 0.65
MPI P34949 2/20 0.65
ATG4B Q9Y4P1 2/20 0.65
S1PR2 O95136 2/20 0.65
SMAD3 P84022 2/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24989323 0.84 TDP2 (0.58) TDP2KDM4CNPC1POLBMAPT
SCHEMBL2180986 0.79 TDP2 (1.00) TDP2KDM4CNPC1POLBMAPT
SCHEMBL3470636 0.73 TDP2 (0.65) TDP2KDM4CNPC1POLBMAPT
SCHEMBL2180811 0.73 TDP2 (0.77) TDP2KDM4CNPC1POLBMAPT
SCHEMBL13272699 0.72 TDP2 (0.70) TDP2KDM4CNPC1POLBMAPT
SCHEMBL3471248 0.72 TDP2 (0.63) TDP2KDM4CNPC1POLBMAPT
SCHEMBL3472625 0.71 TDP2 (1.00) TDP2KDM4CNPC1POLBMAPT
SCHEMBL15032586 0.71 TDP2 (1.00) TDP2KDM4CNPC1POLBMAPT
SCHEMBL24988965 0.70 TDP2 (0.45) TDP2KDM4CNPC1POLBMAPT
SCHEMBL2183740 0.69 TDP2 (1.00) TDP2KDM4CNPC1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2010072807-A2 INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE FONDATION JEROME LEJEUNE (FR) 2010-07-01 WO claimed
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-06-15 US disclosed
EP-4129282-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF NATURAL MEDICINE INSTITUTE OF ZHEJIANG YANGSHENGTANG CO., LTD. (CN) 2023-02-08 EP disclosed
WO-2010072807-A2 INHIBITORS OF CYSTATHIONINE BETA SYNTHASE TO REDUCE THE NEUROTOXIC OVERPRODUCTION OF ENDOGENOUS HYDROGEN SULFIDE FONDATION JEROME LEJEUNE (FR) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181524-A1 PHARMACEUTICAL COMBINATION AND USE THEREOF TCF4, TCF7L2, CTNNB1 TDP2 2515/4885KDM4C 2237/4885NPC1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.